Study of ONO-8539 in Patients With Overactive Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

April 30, 2010

Conditions
Overactive Bladder
Interventions
DRUG

Placebo

Placebo / 12 weeks

DRUG

Tolterodine

4mg / 12 weeks

DRUG

ONO-8539

low dose / 12 weeks

DRUG

ONO-8539

medium dose / 12 weeks

DRUG

ONO-8539

higher dose / 12 weeks

Trial Locations (50)

Unknown

Brno

Jindřichův Hradec

Olomouc

Opava

Pilsen

Prague

Štětí

Ústí nad Labem

Duisburg

Hagenow

Krumbach

Magdeburg

Mülheim

Weiden

Budapest

Dombóvár

Nyíregyháza

Szeged

Szekszárd

Heerlen

Maastricht

The Hague

Tilburg

Winterswijk

Bialystok

Bielsko-Biala

Gdansk

Gdynia

Katowice

Lodz

Lublin

Mysłowice

Warsaw

Arad

Bihor

Bucharest

Timuș

Moscow

Rostov-on-Don

Saint Petersburg

Gothenburg

Kungälv

Stockholm

Umeå

Uppsala

Chernivtsi

Donetsk

Kharkiv

Kyiv

Zaporizhzhya

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY